Cantel Medical (CMD) Reports In-Line Q3 EPS, Revenues Miss

Cantel Medical (NYSE: CMD) reported Q3 EPS of $0.60, in-line with the analyst estimate of $0.60. Revenue for the quarter came in at $217.27 million versus the consensus estimate of $219.56 million.

Jørgen B. Hansen, President and Chief Executive Officer, stated, "We are pleased to report record sales and strong earnings performance this quarter. Our 13.1% reported sales increase was driven by organic growth of 7.6%, the impact from acquisitions of 4.0%, and a favorable impact from foreign currency of 1.5%. We continue to perform well internationally where sales were up 25.6% overall, and our US business had a strong quarter with 9.1% growth."

For earnings history and earnings-related data on Cantel Medical (CMD) click here.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• Telesat Corporation (TSAT) Misses Q2 EPS by 1006c
• Bragg Gaming Group Inc. (BRAG) Tops Q2 EPS by 2c